Zacks.com on MSN8d
GSK's Jemperli Gets EU Nod for Expanded Use in Endometrial Cancer
GSK plc GSK announced that the European Commission has granted approval for the expanded use of Jemperli (dostarlimab) plus ...
Hosted on MSN1d
GSK and University of Oxford partner for cancer vaccine research
GSK and the University of Oxford have entered a new research partnership to launch an immuno-prevention programme to explore ...
Europe Drug Regulator Expands GSK's Jemperli/Chemo Combo To Adult Patients With Advanced Endometrial Cancer
GSK's Jemperli wins EU approval for broader use in advanced endometrial cancer, showing improved survival and significant ...
PMLiVE9d
GSK’s Jemperli combination approved by EC for expanded endometrial cancer use
GSK’s Jemperli is designed to help the body’s immune system find and attack cancer cells, and is already approved in the EU ...
GSK announces expanded EU approval in endometrial cancer for Jemperli combo
GSK (GSK) announced the European Commission has approved Jemperli, or dostarlimab, in combination with chemotherapy for first-line treatment of ...
The Pharma Letter9d
EC expands approval for Jemperli
The European Commission has approved Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for ...
GSK: European Commission Expands Jemperli Plus Chemotherapy Approval - Quick Facts
GSK plc (GSK, GSK.L) announced the European Commission has approved Jemperli in combination with chemotherapy for first-line ...
EU regulators expand usage of GSK's Jemperli cancer drug
European regulators have expanded the usage of GSK's Jemperli drug for endometrial cancer, the pharmaceutical firm announced ...
Yahoo Finance8d
Europe Drug Regulator Expands GSK's Jemperli/Chemo Combo To Adult Patients With Advanced Endometrial Cancer
The label for Jemperli plus chemotherapy in the U.S. was expanded to all adult patients with primary advanced or recurrent endometrial cancer in August 2024. Recently, GSK agreed to acquire IDRx ...